Michael D Hogarty
Overview
Explore the profile of Michael D Hogarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
7217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wolpaw A, Grossmann L, Dessau J, Dong M, Aaron B, Brafford P, et al.
Proc Natl Acad Sci U S A
. 2022 Feb;
119(6).
PMID: 35121657
Immunotherapy has revolutionized cancer treatment, but many cancers are not impacted by currently available immunotherapeutic strategies. Here, we investigated inflammatory signaling pathways in neuroblastoma, a classically "cold" pediatric cancer. By...
12.
Go R, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler E, Campbell P, et al.
J Natl Compr Canc Netw
. 2021 Nov;
19(11):1277-1303.
PMID: 34781268
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly...
13.
Irwin M, Naranjo A, Zhang F, Cohn S, London W, Gastier-Foster J, et al.
J Clin Oncol
. 2021 Jul;
39(29):3229-3241.
PMID: 34319759
Purpose: Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International...
14.
Zanotti S, Vanhauwaert S, Van Neste C, Olexiouk V, Van Laere J, Verschuuren M, et al.
Sci Rep
. 2021 Jul;
11(1):14454.
PMID: 34262099
MYCN is an oncogenic driver in neural crest-derived neuroblastoma and medulloblastoma. To better understand the early effects of MYCN activation in a neural-crest lineage context, we profiled the transcriptome of...
15.
Gamble L, Purgato S, Henderson M, Di Giacomo S, Russell A, Pigini P, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33918978
Ornithine decarboxylase (ODC1), a critical regulatory enzyme in polyamine biosynthesis, is a direct transcriptional target of MYCN, amplification of which is a powerful marker of aggressive neuroblastoma. A single nucleotide...
16.
Granger M, Naranjo A, Bagatell R, Dubois S, McCune J, Tenney S, et al.
Transplant Cell Ther
. 2021 Apr;
27(6):490.e1-490.e8.
PMID: 33823167
Consolidation using high-dose chemotherapy with autologous stem cell transplantation (ASCT) is an important component of frontline therapy for children with high-risk neuroblastoma. The optimal preparative regimen is uncertain, although recent...
17.
Kawano A, Hazard F, Chiu B, Naranjo A, LaBarre B, London W, et al.
Am J Surg Pathol
. 2021 Mar;
45(8):1075-1081.
PMID: 33739795
Stage 4S neuroblastoma (4SNB) is associated with spontaneous tumor regression and an excellent prognosis. However, a small group of the patients have a poor prognosis. One hundred eighty-five stage 4SNB...
18.
Jain P, Surrey L, Straka J, Russo P, Womer R, Li M, et al.
Pediatr Blood Cancer
. 2021 Feb;
68(6):e28933.
PMID: 33565241
Pediatric histiocytic neoplasms are hematopoietic disorders frequently driven by the BRAF-V600E mutation. Here, we identified two BRAF gene fusions (novel MTAP-BRAF and MS4A6A-BRAF) in two aggressive histiocytic neoplasms. In contrast...
19.
Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, et al.
Nat Commun
. 2021 Jan;
12(1):511.
PMID: 33479234
The ability to utilize preclinical models to predict the clinical toxicity of chimeric antigen receptor (CAR) T cells in solid tumors is tenuous, thereby necessitating the development and evaluation of...
20.
Brady S, Liu Y, Ma X, Gout A, Hagiwara K, Zhou X, et al.
Nat Commun
. 2020 Oct;
11(1):5183.
PMID: 33056981
Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. To better understand neuroblastoma pathogenesis, here we analyze whole-genome, whole-exome and/or transcriptome data from 702 neuroblastoma samples. Forty percent of samples...